Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2006

Open Access 01-06-2006 | Review

Adding pharmacogenomics to the development of new marine-derived anticancer agents

Authors: José Jimeno, Miguel Aracil, Juan Carlos Tercero

Published in: Journal of Translational Medicine | Issue 1/2006

Login to get access

Abstract

Nature has always been a highly productive tool in the development of anticancer therapies. Renewed interest in the potential of this tool has recently been sparked by the realization that the marine ecosystem can be used for the discovery and development of new compounds with clinical potential in advanced resistant tumors. These compounds can be incorporated into combination approaches in a chronic therapy scenario. Our marine anticancer program is using the sea to develop new agents with activity in resistant solid tumors and to identify new cellular targets for therapeutic intervention. This review describes the integration of different pharmacogenomic tools in the development of Yondelis™, Aplidin® and Kahalalide F, three marine-derived compounds currently in Phase II or III development. Our results are reinforcing the targeted selectivity of these agents and opening the gates for customized therapies in cancer patients in the near future.
Appendix
Available only for authorised users
Literature
1.
Hurwitz H, Fehrenbacher L, Novotny W: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350: 2335-2342. 10.1056/NEJMoa032691.CrossRefPubMed
2.
Cunninham D, Humblet Y, Siena S: Cetuximab monotherapy plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med. 2004, 351: 337-345. 10.1056/NEJMoa033025.CrossRef
3.
Lenz HJ: The use and development of germline polymorphisms in clinical oncology. J Clin Oncol. 2004, 22: 2519-2521. 10.1200/JCO.2004.04.900.CrossRefPubMed
4.
Rosell R, Tarón M, O'Brate A: Predictive molecular markers in non-small cell lung cancer. Curr Opinion in Oncol. 2001, 13: 101-109. 10.1097/00001622-200103000-00004.CrossRef
5.
Rosell R, Ichinose Y, Tarón M: Non small cell lung cancer (NSCLC) tumors from Gefitinib-responsive patients (pts) harbor EGFR kinase domain mutations. Ann Oncol. 2002, 166-(abstr 6280), Suppl 3
6.
Lynch TJ, Bell DW, Sordella R: Activating mutations in the epidermal growth factor receptors underlying responsiveness of non small cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938.CrossRefPubMed
7.
Jimeno J, López Martín JA, Ruiz Casado A, Izquierdo MA, Scheuer P, Rinehart K: Progress in the clinical development of new marine derived anticancer compounds. Anticancer Drugs. 2004, 15: 321-329. 10.1097/00001813-200404000-00003.CrossRefPubMed
8.
Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996, 35: 13303-13309. 10.1021/bi960306b.CrossRefPubMed
9.
Moore BM, Seaman FC, Hurley LH: NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc. 1997, 119: 5475-5476. 10.1021/ja9704500.CrossRef
10.
Minuzzo M, Marchini S, Broggini M, Faircloth GT, D'Incalci M, Mantovani R: Interference of transcriptional activation by the anti-neoplastic drug ET-743. Proc Natl Acad Sci USA. 2000, 97: 6780-6784. 10.1073/pnas.97.12.6780.PubMedCentralCrossRefPubMed
11.
Jin S, Gorfajn B, Faircloth G, Scotto KW: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA. 2000, 97: 6775-6779. 10.1073/pnas.97.12.6775.PubMedCentralCrossRefPubMed
12.
Yovine A, Riofrio M, Blay JY: Phase II study of Yondelis (Trabectedin ET-743) in advanced/pre-treated soft tissue sarcoma patients. J Clin Oncol. 2004, 22: 890-899. 10.1200/JCO.2004.05.210.CrossRefPubMed
13.
Garcia Carbonero R, Supko JG, Manola J: Phase II and pharmacokinetic study of Ecteinascidin 743 (ET-743) in patients with progressive sarcomas of soft tissues following failure of conventional chemotherapy. J Clin Oncol. 2004, 22: 1-11.CrossRef
14.
Le Cesne L, Blay JY, Judson I: Phase II study of ET-743 in advanced soft tissue sarcomas: An EORTC soft tissue and bone sarcoma group trial. J Clin Oncol. 2005, 23: 576-584. 10.1200/JCO.2005.01.180.CrossRefPubMed
15.
Jimeno J, Maki R, Casali P: Therapeutic impact of ET-743 (Yondelis®, Trabectidin) a new marine derived compound in Sarcoma. Curr Opinion Orthoped. 2003, 14: 419-428. 10.1097/00001433-200312000-00011.CrossRef
16.
Erba E, Bergamaschi D, Bassano L: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001, 37: 97-105. 10.1016/S0959-8049(00)00357-9.CrossRefPubMed
17.
Takebayashi Y, Pourquier P, Zimonjic DB: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001, 7: 961-966. 10.1038/91008.CrossRefPubMed
18.
De Boer J, van Steeg H, Berg RJW: Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition. Cancer Res. 1999, 59: 3489-3494.PubMed
19.
Carnero A, Moneo V, Blanco C: In vitro activity of ET-743 in a panel of low passaged human sarcoma cell lines. Proceedings of the 95th Annual Meeting of the American Association of Cancer Research: 27–31 March, Florida. 2004, 349-abstr 1513
20.
D'Incalci M, Jimeno J: Preclinical and clinical results with the marine natural product trabectedin (Yondelis, Ecteinascidin-743, ET-743). Expert Opinion Investigational Drugs. 2003, 12: 1843-1853. 10.1517/13543784.12.11.1843.CrossRef
21.
Hofseth LJ, Hussain SP, Harris CC: p53, 25 years after its discovery. Trends Pharmacol Sci. 2004, 4: 177-181. 10.1016/j.tips.2004.02.009.CrossRef
22.
Martínez N, Sánchez-Beato M, Carnero A: Transcriptional signature of ET-743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemonaive patients. Mol Cancer Ther. 2005, 4: 814-23. 10.1158/1535-7163.MCT-04-0316.CrossRefPubMed
23.
Martínez N, Camacho FI: The molecular signature of mantle cell lymphoma reveals multiple signals favoring survival. Cancer Res. 2003, 63: 226-232.
24.
Jimeno J, Tarón M, Fernández-Sousa JM: The pharmacogenomics of ET-743 (Yondelis) in sarcoma: Moving towards a targeted approach. Proceedings of the Gene Signature Symposium: 9 March, Madrid. 2005, 47-48.
25.
Van Oosterom A, Maki R, Tarón M: Correlation between the pattern of DNA repair efficiency and the natural history of patients with advanced sarcoma treated with ET-743 (Yondelis). Proceedings of the 29th Congress of the European Society for Medical Oncology: 29 October – 2 November, Vienna. 2004, 197-(abst. 7450)
26.
Lord RVN, Brabender J, Gandara D: Low ERRC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non small cell lung cancer. Clin Cancer Res. 2002, 8: 2286-2911.PubMed
27.
Ventikaraman AR: Tracing the network connecting BRCA and Fanconi anemia proteins. Nature Cancer Rev. 2004, 14: 266-276. 10.1038/nrc1321.
28.
Taron M, Rosell R, Felip E: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004, 13: 2443-9. 10.1093/hmg/ddh260.CrossRefPubMed
29.
Lafarge S, Sylvain V, Ferrara M, Bignon YJ: Inhibition of BRCA1 leads to increased chemoresistance to microtubule interfering agents, an effect that involves the JNK pathway. Oncogene. 2001, 20: 6397-6606. 10.1038/sj.onc.1204812.CrossRef
30.
Erba E, Bassano L, Di Liberti G: Cell cycle phase perturbations and apoptosis induced by Aplidine. Brit J Cancer. 2002, 86: 1510-1517. 10.1038/sj.bjc.6600265.PubMedCentralCrossRefPubMed
31.
García-Fernández LF, Losada A, Alcalde V: Aplidin induces the mitochondrial apotototic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene. 2002, 21: 7533-7544. 10.1038/sj.onc.1205972.CrossRefPubMed
32.
Cuadrado A, García-Fernández LF, González L: Aplidin induces apoptosis in human cancer cells via glutathion depletion and sustained activation of the epidermal growth factor receptor, Src, JMK and p38 MAPK. J Biol Chem. 2003, 278: 241-250. 10.1074/jbc.M201010200.CrossRefPubMed
33.
Broggini M, Marchini S, Borsott P: Aplidine, a new anticancer agent of marine origin, inhibits VEGF secretion and blocks VEGF-VEGF-1 (flt-1) autocrine loop in human leukemic cells molt-41. Leukemia. 2003, 17: 52-59. 10.1038/sj.leu.2402788.CrossRefPubMed
34.
Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A: VEGF inhibition and cytotoxic effect of Aplidine in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol. 2005, 16: 1667-1674. 10.1093/annonc/mdi311.CrossRefPubMed
35.
Straight A, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL: Aplidin reduces growth of anaplastic thyroid cancer xenografts and expression of several angiogenic genes. Cancer Chemother Pharmacol. 2006, 57: 7-14. 10.1007/s00280-005-0014-7.CrossRefPubMed
36.
37.
Bresters D, Broekhuizen A, Faircloth G, Jimeno J, Kaspers G: In vitro cytotoxicity of Aplidine and cross-resistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples; a rational basis for clinical development. Leukemia. 2003, 13: 1338-1343. 10.1038/sj.leu.2402972.CrossRef
38.
Martínez N, Sánchez Beato M, Kaspers G: Sensitivity and resistance of human leukemic blasts to aplidin: molecular signature by gene expression profiling (GEP). Proceedings of the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: 28 September – 1 October, Geneva. 2004, 15-(abstr 37)
39.
Martínez N, Sánchez Beato M, Kaspers G: Molecular signature associated with sensitivity to Aplidin in leukemic blasts from AML and ALL patients. Proceedings of the 6th International Symposium and Expert Workshops on Leukemia and Lymphoma: 17–19 March, Amsterdam. 2005, 92-(abstr P-14)
40.
Banerjee D, Saydam G, Menon LG: Gene expression analyses as an approach to understanding the mechanistic basis of Aplidin action. Proceedings of the 6th International Symposium and Expert Workshops on Leukemia and Lymphoma: 17–19 March, Amsterdam. 2005, 68-(abstr O-44)
41.
Janmaat M, Kruyt F, Jimeno J, Rodriguez JA, Giaccone G: Kahalalide F induces cell death in HER2/neu overexpressing breast cancer cells that is independent of caspase, cathepsin B and cathepsin D activity. Proceedings of the 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy: 23–25 October, Amsterdam. 2003, 60-(abstr B02)
42.
Rademaker-Lakhai J, Horenblas S, Meinhardt W: Phase I clinical and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer. Clinical Cancer Research. 2005, 11: 1854-1862. 10.1158/1078-0432.CCR-04-1534.CrossRefPubMed
43.
Wosikowsky K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE: Identification of epidermal growth factor receptors and c-erb2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst. 1997, 89: 1505-1515. 10.1093/jnci/89.20.1505.CrossRef
44.
Sithanandam G, Smith GT, Masura A: Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phospahatidylinositol 3-kinase/Akt pathway. Carcinogenesis. 2003, 24: 1581-1592. 10.1093/carcin/bgg125.CrossRefPubMed
45.
Janmaat M, Rodriguez J, Jimeno J, Kruyt F, Giaccone G: Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol. 2005, 68: 502-510.PubMed
46.
Grasselli G, Malossi A, Marsoni S: Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Yondelis®) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. Proc Am Soc Clin Oncol. 2003, 22: 135-(abstr 542)
47.
Gianni L, Grasselli G, De Braud F: Definition of the least toxic sequence (LTS) and optimal therapeutic dose of Yondelis ™ (ET-743; trabectedin) in combination with doxorubicin (doxo) in patients with untreated metastatic soft tissue sarcomas (STS) and advanced pre-treated anthracycline-naïve breast cancer patients (ABC). Proceedings of the 15th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: 17–21 November, Boston. 2003, 62-(abstr A49)
48.
Chu Q, Schwartz G, Patnaik A: Phase I and pharmacokinetic study of sequential paclitaxel followed by trabectedin (ET-743) in 24h every 2 weeks in patients with advanced or metastatic cancer. Proceedings of the 29th Congress of the European Society for Medical Oncology: 29 October – 2 November, Vienna. 2004, 107-(abstr 398P)
49.
Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zaniboni F, Gianni L, Marsoni S, Jimeno J, D'incalci M, Dall'O E, Colombo N: Trabectedin (ET-743) for women with ovarian carcinoma after failure of platinum-taxanes. J Clin Oncol. 2005, 23: 1867-1874. 10.1200/JCO.2005.09.032.CrossRefPubMed
50.
Eisen T, Thomas J, Van Oosterom A: Aplidin as second line therapy in patients with advanced melanoma. Ann Oncol. 2004, 15: 196-(abstr 747O)
51.
Lee W, Lockhart AC, Kim RB, Rothemberg MC: Cancer Pharmacogenomics. Powerful tools in cancer chemotherapy and drug development. The Oncologist. 2005, 10: 104-111. 10.1634/theoncologist.10-2-104.CrossRefPubMed
Metadata
Title
Adding pharmacogenomics to the development of new marine-derived anticancer agents
Authors
José Jimeno
Miguel Aracil
Juan Carlos Tercero
Publication date
01-06-2006
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2006
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-4-3

Other articles of this Issue 1/2006

Journal of Translational Medicine 1/2006 Go to the issue

Research

The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection

Research

Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas

Methodology

Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture

Research

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant

Methodology

Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: applications and preliminary results in a murine model

Research

Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits